The transaction is set to be completed in the first quarter of 2020.
Sartorius announced it has signed an agreement to acquire parts of Danaher’s Life Science Portfolio for $750 million in cash on Oct. 21, 2019.
According to a press release, the agreement highlights three businesses that are part of the Washington, DC-based science and technology company Danaher Life Science’s portfolio. The businesses include:
Sartorius plans to expand sectors of its business to fit the acquired companies, according to the release.
“The portfolio proposed for acquisition represents an excellent strategic fit with Sartorius,” said Dr. Joachim Kreuzburg, Sartorius’ CEO, in the press release. “With the Octet platform of FortéBio, we will add a broadly accepted and differentiated technology for advancing and simplifying drug discovery to our lab division’s portfolio. The chromatography hardware and resins and the microcarrier businesses broaden our strong bioprocessing offering, particularly in the downstream area. We look very much forward to welcoming the new teams to Sartorius and to jointly combine our capabilities for the benefit of our biopharma and life science customers.”
The transaction is set to be completed in the first quarter of 2020.
Source: Sartorius
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.